Back to today’s briefing

Story perspectives

Harmony Biosciences Soars; Illumina Stake Cut by abrdn

2/7/2025

42 3

Summary

Story summary

Harmony Biosciences (HRMY) is celebrating a remarkable preliminary revenue of $201 million for Q4 2024, signaling a promising trajectory for 2025. In a contrasting move, abrdn plc has slashed its stake in Illumina (ILMN) by 35%, yet other investors are doubling down. Analysts are optimistic, holding a "Moderate Buy" rating for ILMN, showcasing a resilient market outlook.

History

Historical Context

Harmony Biosciences' Q4 2024 revenue of $201 million reflects a resurgence in biotech, reminiscent of the 1990s biotech boom. Similar to then, investors are optimistic despite mixed signals, as seen with abrdn plc's stake reduction in Illumina. Historical trends show resilience amid market fluctuations.

1 of 2

Story summary

Harmony Biosciences (HRMY) is celebrating a remarkable preliminary revenue of $201 million for Q4 2024, signaling a promising trajectory for 2025. In a contrasting move, abrdn plc has slashed its stake in Illumina (ILMN) by 35%, yet other investors are doubling down. Analysts are optimistic, holding a "Moderate Buy" rating for ILMN, showcasing a resilient market outlook.

1 / 2